Choose ALUNBRIG® (brigatinib): An ALK Inhibitor With Broad Mutational Coverage

ALUNBRIG has demonstrated broad mutational coverage and activity in the CNS1

""

ALUNBRIG Mechanism of Action (MOA)

  • A tyrosine kinase inhibitor with in vitro activity at clinically achievable concentrations against multiple kinases including ALK, ROS1, insulin-like growth factor-1 receptor (IGF-1R), and FLT-3 as well as EGFR deletion and point mutations1
  • Inhibited autophosphorylation of ALK and ALK-mediated phosphorylation of the downstream signaling proteins STAT3, AKT, ERK1/2, and S6 in in vitro and in vivo assays1
  • ALUNBRIG (brigatinib) inhibited the in vitro proliferation of cell lines expressing EML4-ALK and NPM-ALK fusion proteins1
  • Demonstrated dose-dependent inhibition of EML4-ALK+ NSCLC xenograft growth in mice1
  • At clinically achievable concentrations (≤500 nM), brigatinib inhibited the in vitro viability of cells expressing EML4-ALK and 17 mutant forms associated with resistance to ALK inhibitors including crizotinib, as well as EGFR-Del (E746-A750), ROS1-L2026M, FLT3-F691L, and FLT3-D835Y1
  • Brigatinib exhibited in vivo antitumor activity against 4 mutant forms of EML4-ALK, including G1202R and L1196M mutants identified in NSCLC tumors in patients who had progressed on crizotinib.1 See more
Brigatinib mechanism of action illustration.

In Vitro: ALUNBRIG Inhibited 17
ALK Inhibitor-Resistant Mutations2,3

ALUNBRIG exhibited in vivo antitumor activity against 4 mutant forms of EML4-ALK, including the G1202R and L1196M mutants identified in NSCLC tumors in patients who had progressed on crizotinib.

Comparison chart for 17 ALK inhibitor­resistant mutations inhibited by ALUNBRIG® in vitro.

ALUNBRIG Demonstrated In Vivo Antitumor Activity in the CNS

ALUNBRIG reduced tumor burden and prolonged survival in mice with an ALK-driven tumor cell line implanted intracranially

Brigatinib (ALUNBRIG) is recommended Category 1 treatment and a preferred first-line treatment for mNSCLC 4a,b,c

aWhen an ALK rearrangement is discovered prior to first-line systemic therapy.
bThe NCCN Guidelines® for NSCLC provide recommendations for individual biomarkers that should be tested and recommend testing techniques, but do not endorse any specific commercially available biomarker assays or commercial laboratories.
cSee the NCCN Guidelines for detailed recommendations, including other preferred treatment options.


AACR, American Association for Cancer Research; ALK, anaplastic lymphoma kinase; CNS, central nervous system; NSCLC, non-small cell lung cancer.